HIV-specific cytotoxic T-lymphocytes (CTL) play a critical role in containing HIV viremia in acute infection or in situation of spontaneous control, rendering them attractive candidates for vaccine strategies. However vaccines developed so far have failed to protect against HIV infection, this despite generating CTL responses. The fact that CTL responses against certain areas of the virus may be more effective at controlling HIV replication than CTL with other specificities suggests that vaccine should elicit selected CTL responses associated with protection. Effective presentation of the cognate epitopes by HIV-infected cells is a crucial condition for protective CTL responses. However, there is still surprisingly little understanding of intracellular mechanisms governing the presentation of HIV epitopes recognized by CD8 T cells. Most studies on HIV- specific CTL functions utilize cognate epitopes in the form of synthetic peptides, thus bypassing all intracellular steps of protein degradation leading to the presentation of epitopes. HIV infects several CD4-expressing subsets (CD4 T cells, monocyte/macrophages and dendritic cells) that will present HIV epitopes. Whether these subsets present similar epitopes with identical kinetics is unknown. Variations in epitope presentation between subsets may affect the antiviral efficacy of CTL. Conversely identifying areas of HIV that are efficiently processed into epitopes in all subsets is of highest importance for the identification of protective CTL responses and selection of immunogens. Building on novel epitope processing assays, we showed preferential processing of some HIV epitopes, a property that relies on motifs we used to alter the production of irrelevant epitopes. We also identified a novel factor involved in epitope processing efficiency, namely the highly variable intracellular stability of optimal HIV epitopes, also driven by specific motifs. Finally we show that CD4 T cells have lower processing activities than monocytes, which affects the kinetics and antigenicity of degradation products from HIV proteins. These data suggest that epitope production is controlled by rules that could be exploited to design customized immunogens. Specifically we propose to: 1) Determine whether CTL responses associated with spontaneous control of HIV viremia efficiently recognize and kill all HIV-infectable cell subsets. Taking advantage of a large cohort of controllers and progressors, we will assess the functionality of CD8 T cells stimulated by various HIV-infected subsets. 2) Identify peptides commonly produced in distinct antigen processing pathways of infectable subsets contributing to spontaneous controlled viremia. Using nanoparticles to target HIV proteins inside cell subsets, we will identify antigenic peptides produced by all subsets. 3) Design and test sequence signatures leading to the selective presentation of protective HIV epitopes. This proposal relies on a cross-disciplinary collaborative approach involving computational science, bioengineered tools and biochemical and immunological assays of epitope processing and CTL functions designed for primary cells.

Public Health Relevance

HIV-specific CD8 T cells are able to kill HIV-infected cells because infected cells display pieces of virus called epitopes. Deciphering the mechanisms of production and presentation of HIV epitopes stimulating efficient immune responses is key to rational vaccine design. This project seeks to identify immune responses and epitopes presented by HIV-infected cell subsets from persons with spontaneously undetectable viremia (controllers) and to define factors governing the efficiency of epitope processing that will enable selected presentation of protective epitopes in immunogens.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SV-A (M2))
Program Officer
Sharma, Usha K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Kourjian, Georgio; Rucevic, Marijana; Berberich, Matthew J et al. (2016) HIV Protease Inhibitor-Induced Cathepsin Modulation Alters Antigen Processing and Cross-Presentation. J Immunol 196:3595-607
Rucevic, Marijana; Kourjian, Georgio; Boucau, Julie et al. (2016) Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses. J Virol 90:8605-20
Dinter, Jens; Duong, Ellen; Lai, Nicole Y et al. (2015) Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape. PLoS Pathog 11:e1004725
Kourjian, Georgio; Xu, Yang; Mondesire-Crump, Ijah et al. (2014) Sequence-specific alterations of epitope production by HIV protease inhibitors. J Immunol 192:3496-506
Dinter, Jens; Gourdain, Pauline; Lai, Nicole Y et al. (2014) Different antigen-processing activities in dendritic cells, macrophages, and monocytes lead to uneven production of HIV epitopes and affect CTL recognition. J Immunol 193:4322-34
Rucevic, Marijana; Boucau, Julie; Dinter, Jens et al. (2014) Mechanisms of HIV protein degradation into epitopes: implications for vaccine design. Viruses 6:3271-92
Gourdain, Pauline; Boucau, Julie; Kourjian, Georgio et al. (2013) A real-time killing assay to follow viral epitope presentation to CD8 T cells. J Immunol Methods 398-399:60-7
Vaithilingam, Archana; Lai, Nicole Y; Duong, Ellen et al. (2013) A simple methodology to assess endolysosomal protease activity involved in antigen processing in human primary cells. BMC Cell Biol 14:35
Zhang, Shao Chong; Martin, Eric; Shimada, Mariko et al. (2012) Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J Immunol 188:5924-34
Lazaro, Estibaliz; Kadie, Carl; Stamegna, Pamela et al. (2011) Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J Clin Invest 121:2480-92